|
Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane). |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Foundation One Inc; Lilly; Lilly; Medivation/Astellas; Nektar; Pfizer; Pharmacyclics |
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst) |
|
|
Honoraria - Clovis Oncology; Novartis |
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; Janssen-Cilag; Pfizer |
Speakers' Bureau - Pfizer |
Research Funding - Sanofi/Aventis (Inst) |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen-Cilag |
Speakers' Bureau - Astellas Pharma; Bayer; Ferring |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Ferring (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ferring; Janssen-Cilag |
|
|
Honoraria - Astellas Pharma; Ipsen; JW Pharmaceutical; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; Astellas Pharma; Handok; Ipsen; Janssen; JW Pharmaceutical; Takeda |
Research Funding - AstraZeneca; Bayer; Janssen; Myovant Sciences; Pfizer; Roche |
|
Andrea Juliana Pereira de Santana Gomes |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Ipsen; Janssen; Pfizer |
Research Funding - Bayer; Janssen Research & Development |
|
|
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Novartis; Pfizer; Roche; Takeda |
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; MSD Oncology |
|
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Janssen-Cilag (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Janssen-Cilag |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; MSD; Ono Pharmaceutical; Pfizer |
Consulting or Advisory Role - Ono Pharmaceutical; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
No Relationships to Disclose |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; ESSA; Janssen; Roche; Sanofi |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly/ImClone (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst) |